PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of risk management plan for Nurofen Retard 300 mg tabletten met verlengde afgifte.

This is a summary of the risk management plan (RMP) for Nurofen Retard 300 mg tabletten met verlengde afgifte. The RMP details important risks of Nurofen Retard 300 mg tabletten met verlengde afgifte, how these risks can be minimised, and how more information will be obtained about Nurofen Retard 300 mg tabletten met verlengde afgifte's risks and uncertainties (missing information).

Nurofen Retard 300 mg tabletten met verlengde afgifte's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Nurofen Retard 300 mg tabletten met verlengde afgifte should be used.

I. The medicine and what it is used for

Nurofen Retard 300 mg tabletten met verlengde afgifte is authorised for the short-term relief of mild to moderate pain expected to last longer than 6-8 hours, such as backache, muscular pain, joint pain, period pain, and dental pain (see SmPC for the full indication). It contains ibuprofen as the active substance and it is given by oral administration

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Nurofen Retard 300 mg tabletten met verlengde afgifte together with measures to minimise such risks and the proposed studies for learning more about Nurofen Retard 300 mg tabletten met verlengde afgifte's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Nurofen Retard 300 mg tabletten met verlengde afgifte are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Nurofen Retard 300 mg tabletten met verlengde afgifte. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Important Identified Risks	None.
Important Potential Risks	None.
Missing Information	None.

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Nurofen Retard 300 mg tabletten verlengde afgifte.

II.C.2 Other studies in post-authorisation development plan

There are no other studies required for Nurofen Retard 300 mg tabletten met verlengde afgifte.